CA1077028A - PROCESS FOR PREPARATION OF 1.alpha.,2.alpha.-DIHYDROXY-CHOLECALCIFEROL - Google Patents
PROCESS FOR PREPARATION OF 1.alpha.,2.alpha.-DIHYDROXY-CHOLECALCIFEROLInfo
- Publication number
- CA1077028A CA1077028A CA329,124A CA329124A CA1077028A CA 1077028 A CA1077028 A CA 1077028A CA 329124 A CA329124 A CA 329124A CA 1077028 A CA1077028 A CA 1077028A
- Authority
- CA
- Canada
- Prior art keywords
- alpha
- cholesta
- beta
- triol
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Steroid Compounds (AREA)
Abstract
ABSTRACT
A process for preparing cholesta-5,7-diene-1.alpha., 3.beta.,25-triol by reduction of a 1.alpha.,2.alpha.-epoxide with a metal hydride such as lithium aluminum hydride. The triol is useful as an intermediate in the preparation of 1.alpha.,25-dihy-droxycholecalciferol.
A process for preparing cholesta-5,7-diene-1.alpha., 3.beta.,25-triol by reduction of a 1.alpha.,2.alpha.-epoxide with a metal hydride such as lithium aluminum hydride. The triol is useful as an intermediate in the preparation of 1.alpha.,25-dihy-droxycholecalciferol.
Description
10~70~8 , ~ . , , :.` . ~ . .
SPECIFICATION
.
This invention relates tO a novel pro_ess for the preparation of 1~,25-dihydroxycholeclaciferol, a compound exhibiting greater activity than vitamins D2 and D3 as measured by its antirachitic properties, and which has value as a nutritional adjuvant, and to intermediates used for preparing the same.
Processes for preparing 1~,25-dihydroxycholecalciferol have heretofore been known (see DeLuca et al, Tetrahedron Letters, page 4147 (1972) and Barton et al, J. Chem. Soo. Chem. Comm., page 203 (1974)). Each of these Icnown processes passes through a triacyl derivative of 1c~,25-dihydroxyprovitamin D3 as an intermediate, and in order ~o form the 5, 7-diene system in this intermediate, - ~ .
SPECIFICATION
.
This invention relates tO a novel pro_ess for the preparation of 1~,25-dihydroxycholeclaciferol, a compound exhibiting greater activity than vitamins D2 and D3 as measured by its antirachitic properties, and which has value as a nutritional adjuvant, and to intermediates used for preparing the same.
Processes for preparing 1~,25-dihydroxycholecalciferol have heretofore been known (see DeLuca et al, Tetrahedron Letters, page 4147 (1972) and Barton et al, J. Chem. Soo. Chem. Comm., page 203 (1974)). Each of these Icnown processes passes through a triacyl derivative of 1c~,25-dihydroxyprovitamin D3 as an intermediate, and in order ~o form the 5, 7-diene system in this intermediate, - ~ .
- 2 - -~Q'770Z8 such severe reactions as introduction of a bromine atom into the 7-position and dehydrobromination must be conducted. Accordingly, in these known processes, hydroxy groups at the 1Q-~ 3,~- and 25-positions should be protected with an acyl group or the like, and the protective groups should naturally be removed in subsequent steps.
A series of such severe reactions as introduction of a bromine atom into the 7-position and dehydrobromination and removal of acyl groups causes formation of various by-products. Consequently, complicated purification means must be adopted and the yield is inevitably lowered.
This is particularly true with the process of Barton et al, since the process passes through 1~, 2cy-epoxycholesta-4, 6-dien-3-one-25-ol as an intermediate, requiring a very dangerous Birch reduction (using liquid ammonia-metallic lithium) and such a cumbersome purification process as preparative TLC, several times in the process steps.
Accordingly, each of these known processes cannot be considered tc~
be an industrially practical process. ~ -The process of this invention provides a method for making t~
intendedcompound, 1~,25-dihydroxycholecalciferol, underverymild conditions, whereby such side reactions as elimination of hydroxyl groups and rearrangement of double bonds can be prevented. In addition, hydroxyl groups need not particularly be protected and the intended compound can be obtained very efficiently without adopting complicated reaction or purification means.
In accordance with this invention, 1~,25-dihydroxycholecalciferol (I) is prepared by isomerizing cholesta-l, 4,6-trien-3-on-25-ol (IX) in the presence of a basic catalyst to form cholesta-l, 5, 7-trien-3-on-25-ol (VIIl), reducing the so formed compound with a metal hydride to form cholesta-1,5,7-trien-3,B~25-diol (VII), reacting the so formed compound with a 1, 2, 4-triazoline-dione derivative represented by the following
A series of such severe reactions as introduction of a bromine atom into the 7-position and dehydrobromination and removal of acyl groups causes formation of various by-products. Consequently, complicated purification means must be adopted and the yield is inevitably lowered.
This is particularly true with the process of Barton et al, since the process passes through 1~, 2cy-epoxycholesta-4, 6-dien-3-one-25-ol as an intermediate, requiring a very dangerous Birch reduction (using liquid ammonia-metallic lithium) and such a cumbersome purification process as preparative TLC, several times in the process steps.
Accordingly, each of these known processes cannot be considered tc~
be an industrially practical process. ~ -The process of this invention provides a method for making t~
intendedcompound, 1~,25-dihydroxycholecalciferol, underverymild conditions, whereby such side reactions as elimination of hydroxyl groups and rearrangement of double bonds can be prevented. In addition, hydroxyl groups need not particularly be protected and the intended compound can be obtained very efficiently without adopting complicated reaction or purification means.
In accordance with this invention, 1~,25-dihydroxycholecalciferol (I) is prepared by isomerizing cholesta-l, 4,6-trien-3-on-25-ol (IX) in the presence of a basic catalyst to form cholesta-l, 5, 7-trien-3-on-25-ol (VIIl), reducing the so formed compound with a metal hydride to form cholesta-1,5,7-trien-3,B~25-diol (VII), reacting the so formed compound with a 1, 2, 4-triazoline-dione derivative represented by the following
- 3 iO~770Z8 general formula (Vl) ¦¦ N-R
N /
O
wherein R represents an organic residue, to form a 1, 4-cyclic adduct represented by the following general formula (V) .
.
~\/\~ OH
':`' ' ~ ' ., ' HO
N )=O
LN
\R
wherein R is as defiried above, reacting the so formed compound with a peroxide to obtain a la, 2a-epoxide compound represented by the following general formula (IV) 1~7~7028 ~ OH
O~ ~
HCi~ / N
~N ~-O
N
\R
whèrein R is as defined above, reducing the so formed compound with a metal hydride to form cholesta-5,7-diene-1~,3,B,25-triol (IIl), irrad-iating the so forme~ compound with ultraviolet rays to form 1c~,25-dihydroxyprevitamin D3 (II), isomerizing the so formed previtamin D3, and recovering la, 25-hydroxycholecalciferol.
DETAILED DESCRIPllON OF ~HE
PREFERRED EMBODIMEN~S
'rhe starting material for the process of this invention, namely, cholesta-l, 4, 6-trien-3-on-25-ol, was obtained from cholesterol as follows. Cholesterol was converted to cholesterol acetate by known procedures after which the cholesterol acetate was converted to 25-hydroxycholesterol acetate utilizing the procedures of A. Rotman and Y. Mazur a. Chem. Soc., Chem. Comm., 1974, 15). ~he recovered 25-hydroxycholesterol acetate was hydrolyzed quantitatively with aqueous 5% KH/MeOH to 25-hydroxycholesterol.
.
' 10770Z~
The 25-hydroxycholesterol was dissolved in dioxane and boiled with 2, 3-dichloro-5, 6-dicyanobenzo-quinone (DDQ) to obtain 25-hydroxy-cholesta-1,4-diene-3-one. This latter compound was subjected to dehydrogenation with chloroanil in the presence of the reduced derivative of DDQ-hydroquinone (2HD~Q) to obtain 25-hydroxy-cholesta- 1, 4, 6-triene-3-one. Alternatively, 25-hydroxy-cholesta- 1, 4, 6-trien-3-one can be obtained by DDQ oxidation of 25-hydroxycholesterol a. J.
Partridge et al, Helv. Chim. Acta 57, 764 (1974))which was converted from 6,~-methoxy-25-hydroxy-3~, 5-cyclo-5~-cholestane.
The cholesta l, 4, 6-trien-3-on-25-ol (IX) is subjected to isomeri-zation in the presence of a basic catalyst whereby the two double bonds located at ~ 4' 5 and a6' 7 positions are isomerized to ,5 ' and ~ 7~ 8 positions respectively. Although any of the well known basic catalysts which promote such isomerization can be used the preferred catalysts _ .
are the alcoholates, such as methylates, ethylates and particularly potassium t-butoxide.
The isomerization is preferably carried out in a solvent which has a high dissol~,ing power for the starting compound including, in general, organic solvents such as ethers, benzene type solvents and hydrocarbon solvents. Solvents such as ether (ethyl), isopropyl ether, tetrahydrofuran, dimethylsulfoxide, and tertiary butyl alcohol find ready application. Excellent results are obtained when, for example, dimethyl-sulfoxide as the solvent and potassium t-butoxide as the catalyst are used in combination for the isomerization reaction. In addition, it is desirable that the reaction be carried out in an atmosphere of inert gas such as argon or nitrogen.
The isomerization reaction can be carried out over a reasonably -broad temperature range although the preferred range is from about 0 tO about 200 C. Higher or lower temperatures may be used but find practical limits in their inlluence upon time of reaction, stability, or instability of reactants to certain temperatures, The compound (VllI) is isolated from the reaction mixture according to a customary procedure, for example, by neutralizing the resulting reaction mixture liquid, extracting it, concentrating the extract and subjecting the concentrate to column chromatography or the like. Because of yield considerations, however, it is preferred that the reaction mixture be forwarded to the next step directly without isolation of the compound (VIII).
The compound (VII) is obtained by reducing compound (VIII) with a metal hydride. Metal hydrides suitable for such reduction, are, for example, lithium aluminum hydride, metal boron hydrides such as sodium boron hydride, potassium boron hydride or lithium boron hydrides, so~ium borohydride and calcium borohydride. It is preferred that the reduction reaction be carried out in a solvent, and use of an ether type solvent such as ether, tetrahydrofuran, 1,2-dimethoxyethane, diglyme (diethylene glycol dimethyl ether3 and the like~ When sodium borohydride or calcium borohydride is used as the metal hydride, a hydroxyl group-containing solvent such as water, methanol and ethanol can be used. The reaction temperature is suitably chosen within a range of from lowered temperatures to elevated temperatures. The preferred temperatur,e range for the reaction is from about 0 C. to about 200 C.
Isolation of the compound (VIl) from the reaction mixture can be accomplished according to customary methods, for example, by neutralizing and extracting the reaction mixture liquid, concentrating the extract and subjecting the concentrate to column chromatography or the like. lt is possible to forward the reaction mixture directly to the subsequent step without isolation of the compound (VlI).
The compound (V) is prepared by reacting compound (VII) with comp~und (Vl). It is preferred that the reaction be carried out in a solvent that does not participate in the reaction.
In general, use of organic solvents such as ethers, benzene-type solvents and hydrocarbon solvents is preferred. Specific examples of preferred solvents are benzene, tetrahydrofuran and methylene chloride.
The reaction temperature is suitably chosen within a range of from lower temperatures to elevated reflux temperatures.
ln the 1, 2, 4-triazoline-3, 5-dione derivative represented by the general formula (VI), any of organic residues inactive to the reaction can be used as R. With the preferred solvents for the reaction it is generally preferred that R be a monocyclic aromatic residue or a lower alkyl group. Specific examples of such preferred organic residues are phenyl, mono-sub3tituted phenyl, methyl and ethyl grQupS.
Isolation of the compound (V) from the reaction mixture is performed by concentrating the reaction mixture, extracting the con-centrate with a solvent such as benzene or methylene chloride, and subjecting the extract to column chromatography.
The compound (IV) is prepared by react ing compound (V) with a peroxide. An organic peracid is preferably used as the peroxide.
As the peracid, there can be employed, aromatic peracids such as perbenzoic acid and m-chloroperbenzoic acid and aliphatic peracids such as permaleic acid, peracetic acid and pertrifluoroacetic acid.
lt is preferred that the reaction be carried out in a solvent, for example, ~0770Z8 ethers, such as ethyl ether and tetrahydrofuran chlorinated hydrocarbon solvents, such as chloroform and methylene chloride, alkyl esters of organic acids such as ethyl acetate, and fatty acids such as acetic acid the peroxide being present in an amount of about 1 to 5 moles per mole of compound V. In view of the inactivity toward the peroxide used and the dissolving power toward the reactants, use of hydrocarbon solvents such as methylene chloride and chloroform is especially preferred. The reaction temperature is chosen within a rarlge of from lowered temperatures to elevated temperatures depending on the kind of the peroxide used.
The compound (lIl) is obtained by reducing compound (IV) ~
with a metal hydride. The metal hydrides which are preferably employed are lithium aluminum hydride and lithium borohydride. The reaction is normally carried out in a solvent, such as the ether type solvents, for example, ethyl ether, tetrahydrofuran, 1,2-dimethoxyethane and diglyme, which are especially preferred. The reaction temperature .
is chosen suitably within a range of from lowered tempexatures to elevated temperatures, for example from about 50 to about 150~ C.
Isolation of the compound (lIT) from the reaction mixture is performed according to customary methods, e. g. by decomposing the excessive metal hydride, extractlng the reactl;on mixture, concentrating the extract and subjecting the concentrate to column chromatography or the like.
Compound (III) is then irradiated with ultraviolet rays to form compound (II) in which the ring B of the steroid skeleton is cleaved.
The irradiation IS generally conducted in a solvent. Hydrocarbon-type solvents, ether-type solvents and alcohols can be readily employed.
1~770Z~3 Examples of preferable hydro_arbon-type solvents are saturated hydrocarbon solvents, especially those having a low boiling point, such as hexane and octane. Ether type solvents which are preferably employed are the low-boiling-point saturated ethers, such as ethyl ether and tetrahydrofuran and the preferable alcohols are the lower alcohols such as methanol and ethanol. It is preferred that the reaction be carried out at a temperature approximating room temperature and in an atmosphere of an inert gas such as argon. The time for irradiation of ultraviolet rays varies depending upon the intensity of the ultraviolet source lamp and the reaction scale. In general, the irradiation time is within a range of from scores of seconds to several hours.
Compound (II) is isolated from the reaction mixture according to customary methods, for example; by concentrating the reaction mixture and subjecting the concentrate to chromatography or the like. It is possible .. ~
to forward the reaction mixture to the subsequent step directly without isolation of the compound (II).
The compound (I) is formed by isomerizing the compound (II) with thermal equilibrium being established between the compound (II) and the desired end compound (I). The isomerization reaction is carried out in accordance with known and customary methods, for example, by allowing the compound (II) to stand for a period in the dark at room temperature, or by heating it in a solvent. Any solvents which are inactive to the reaction e. g., hydrocarbon-type s~lvents, ether-type solvents and alcohols can be used. Preferred solvents are those having a low boiling point and a high dissolving power for the compound (II), such as hexane, isoctane, toluene, ether and te~rahydrofuran. Depending upon the reaction conditions the reaction tlme may range from several hours ~ 0770Z8 tO several weeks. \7\1hen cornpound (II) is allowed to stand in the dar};, it is preferred that the reaction continue for several weeks, When ~he reaction is carried out under heating and refluxing, it is preferred thal the reaction continue only for several hours.
Isolation of the end product, 1~, 25-dihydroxycholecalciferol from the reaction mixture is accomplished by known and custornary purification means such as extraction, recrystallization, column chromatography and partition chromatography. Column chromatography using a column packed with Sephadex (manufactured by Pharmacia Pine Chemicals) is especially effective. I~nisomerized compound (II) is also obtained in the separation procedure and this unisomerized compound (II) can be recycled for further isomerization after recovery.
- Each of intermediate compounds (VlII), (VII), (V), (IV), (III) and (II) formed in the process of this invention are novel and form another . ~ ., aspect of this i~vention.
A more complete understandlng of the invention can be obtained from reference to the following sp~cific examples which are included for purposes of illustration only and are not intended to belimiting.
Example 1 1. Preparation of cholesta- 1, 5, 7-trien-3-on-25-ol.
A reaction vessel was charged with 125 ml of dry dimethylsulfoxide and 2. 5 g of choles$a-1, 4, 6-trien-- 3-on-25-ol was suspended in the dimethylsulfoxide. The suspension was heated, and 10 ml of dry ether was added to the resulting milky suspension tO obtain a transparent solution. ~he reaction vessel was filled wilh dry argon gas. Powdery potassium t-buloxide prepared from 1. 25 g potassium` and 50 ml of butanol was added al one time to the solution under ice cooling and wilh violenl agilalion.
*Trade Mark - 1 l -~0770Z8 The reaction mixture liquid was violently agitated for 12 minutes and was then poured into ice water saturated with carbon dioxide gas, which was prepared by adding dry ice to water. The mixture was then extracted with 600 ml of ether cooled to 0 to S C. The extract was promptly washed with cooled water saturated with a large quantity of carbon dioxide until the washing liquid became neutral, and the ether was then distilled off to obtain crude cholesta- 1, 5, 7-trien-3-on-25-ol.
2. Preparation of cholesta-l, 5, 7-triene-3~, 25-diol.
100 ml of an ethanol solution containing 2. 5 g of sodium borohydride was added dropwise under agitation - -to 110 ml of methanol containing 4. 9 g of calcium chloride, which was cooled below - 10 C. The mixture was agitated for 20 minutes while maintaining the temperature at about -10 C. Then, 100 ml of the ether solution containing crude cholesta- 1, 5, 7-trien-3-on-25-ol, which was prepared in 1.
above, was added dropwise to the above mixture. The reaction mixture was further agitated at -10 C. for 1 hour and at 0 C. for 1 hour, and was then neutralized with 10% acetic acid after which the solvent was distilled off under reduced pressure. The residue was extracted with methylene chloride and the extract was washed with water and dried with magnesium sulfate. Methylene chloride was distilled off to obtain crude cholesta- 1, 5, 7-triene-3~, 25-diol (about 1 g).
3. Preparation of 1,4-cyclized adduct of cholesta-1,5,7-triene-3~B, 25-diol and 4-phenyl- 1, 2, 4-triæoline-3, S-dione.
About S00 mg of 4-phenyl-1,2,4-triæoline-3,5-dione was added little by little under agitation to 50 ml of a methylene chloride solution containing the crude cholesta-1,5,7-triene-3~,25-diol ~about 1 g)obtained in 2. above, until the methylene chloride solution became red. 'rhe solution was agitated at room temperature for 1 hour, and methylene chloride was distilled off and the residue was subjected to column chromatography using a column packed with 200 g of alumina. A chloroform effluent fraction was collected and recrystallized from methand to obtain 1. 4 g (the overall yield being 38.1%) ~, . .
of a cyclic adduct of cholesta-1,5,7-triene-3,~,25-diol and 4-phenyl-1,2,4-triazoline-3,5-dione having a meltin~
point of 159 to 160 C.
Elementary Analysis Values as C35H4704N3- 1/2H2O:
Calculated: C = 72. 13%, H = 8. 30~57c~ N = 7. 21%
Found: C - 72. 06%, H = 8. 15%, N = 7. 45%
Example 2 197. 3 mg of the 1, 4-cyclic adduct obtained in Exarnple 1 was dissolved in 5 ml of chloroform and 237 mg of m-chloroperbenzoic acid was added to the solution after which the mixture was agitated for 40 hours at room temperature. The reaction mixture liquid was diluted with chloroform, washed with a lO~YC aqueous solution of potassium carbonate, dried with anydrous magnesium 107702~i sulfate, and the solvenL was distilled off under reduced pressure. The residue was subjected to silica gel column chromatography. A 1~, 2,~-epoxide of the 1, 4-cyclic adduct melting at 159 to 160. 5 C. was recovered from a fraction primarily eluted with methanol-containing ether, and from the subsequent fraction was obtained 68. 3 mg of a 1~,2~r-epoxide of the 1,4-cyclic adduct having a melting point of 162 to 163. S C. (as measured with respect to a product recrystallized from methanol).
Elementary Analysis Values as C35H47OSN3- 1/2H2O:
Calculated: C = 70.21~C, H - 8. 03~c, N - 7.02%
Found: C = 70. 02%, H - 7. 83%, N = 7. 03%
Example 3 Preparation of cholesta-5, 7-diene- 1~, 3~, 25-triol.
. ~
140. 3 g of the 1~, 2~-epoxide of the 1, 4-cyclic adduct of cholesta- 1, 5, 7-triene-3,8, 25-diol and 4-phenyl- 1-2, 4-triazoline-3,5-dione obtained in Example 2 was dissolved in 15 ml of tetrahydrofuran, and 142 mg of lithium aluminum hydride was added little by little to the solution under agitation. Then, the mixture was mildly refluxed and boiled for 1 hour and cooled, and 20 ml of tetrahydrofuran was added to the reaction mixture. A saturated aqueous solution of Glauber salt was added to the reaction mixture until generation of bubbles was stopped, whereby excessive lithium aluminum hydride was decomposed. The reaction mixture was then filtered, and the residue was washed 3 times with 10 ml of tetrahydrofuran. The organic solvent - 1~ -107'70Z8 layer was dried and the solvent was distilled off, The residue was purified by using a column packed with 20 g of Sephadex LH_20, and a fraction eluted by chloroform-hexane (65: 35 V/V ratio) was collected and recrystallized from ether-hexane to obtain 49. 9 mg of cholesta-5, 7-diene- lc, 3~, 25-t~iol in the form of needles melting at 149 to 152 C.
Mass Spectrum: mk 416(M+), 398, 380, 362 UV Spectrum: il. 2 263, 272, 282, 294 m,u max ~xaniple 4 Preparation of 1~,25-dihydroxyprevitamin D3.
A soluti~n of 31. 5 mg of cholesta-5, 7-d~ene-1~, 3~, 25-triol in 380 ml of ether was exposed for 1 minute to ultraviolet rays through;a Vycor filter in an argon gas atmosphere by using a 400-W high pressure mercury lamp (manufactured by Toshiba). The solvent was distilled off at room ternperature under reduced pressure, and the residue was subjected to colurnn chromatography sing a column packed with 20 g of ~ephadex LH-2~. From a fraction primarily eluted by chloroform-hexane (65: 35 . . . .
V/V Tatio) was obtained 10. 5 mg of oily- 1~, 25-dihydroxy-previtamin D3 ~having a maximum ultraviolet absorption at 260 m,u in an ether solution), and from the subsequent fraction was recovered 14. 3 mg of cholesta-5, 7-diene~
3~, 25-triol. When Ihis compound was exposed IO ultraviolet rays in the same manner as above, 4. 5 mg of lc~, 25-dihydroxy-;
previtamin D3 was obtained.
*Trade Mark 1~ - .
Example 5 Preparation of l ~, 25- dih~droxycholecalci~erol.
The 1~,25-dihydroxyprevitamin D3 obtained in Example 4 above was dissolved in 100 ml of ether, and the solution was allowed to stand at room temperature in the dark in a vessel filled with argon gas for 2 weeks, during which the position of the maxirnum ultraviolet absorp;ion was shifted from 260 m}l to 264 m,~ and the absorption intensity was increased to l. 6 times the initial intensity. The solvent was distilled off under reduced pressure and the residue was subjected to chromatography using a column packed with 10 g of $ephadex LH-20. From a fraction eluted by chloroform-hexane (65: 35 v!v ratio) was obtained 9. 3 mg of oily 1~, 25-dihydrox$~cholecalciferol ~ ..... .
having a melting point of 9i to 99~ C. (as measured with respect to a needle crystal recrystallized from chloroform).
Mass Spectrum: m/e416(M~), 398, 380, 362, 269, 251, 152, 134 UV Spectrum: ~ 264 m,u x lt will be apparent to one of ordinary skill in the art that in the foregoing Examples other solvents and reactants, as well as reaction conditions cornp~tible with such solvents and reactants, such as those set forth in the foregoing specification, can be employed with comparable results.
. . .' .: :
* Trade Mark -- 1( -- .
N /
O
wherein R represents an organic residue, to form a 1, 4-cyclic adduct represented by the following general formula (V) .
.
~\/\~ OH
':`' ' ~ ' ., ' HO
N )=O
LN
\R
wherein R is as defiried above, reacting the so formed compound with a peroxide to obtain a la, 2a-epoxide compound represented by the following general formula (IV) 1~7~7028 ~ OH
O~ ~
HCi~ / N
~N ~-O
N
\R
whèrein R is as defined above, reducing the so formed compound with a metal hydride to form cholesta-5,7-diene-1~,3,B,25-triol (IIl), irrad-iating the so forme~ compound with ultraviolet rays to form 1c~,25-dihydroxyprevitamin D3 (II), isomerizing the so formed previtamin D3, and recovering la, 25-hydroxycholecalciferol.
DETAILED DESCRIPllON OF ~HE
PREFERRED EMBODIMEN~S
'rhe starting material for the process of this invention, namely, cholesta-l, 4, 6-trien-3-on-25-ol, was obtained from cholesterol as follows. Cholesterol was converted to cholesterol acetate by known procedures after which the cholesterol acetate was converted to 25-hydroxycholesterol acetate utilizing the procedures of A. Rotman and Y. Mazur a. Chem. Soc., Chem. Comm., 1974, 15). ~he recovered 25-hydroxycholesterol acetate was hydrolyzed quantitatively with aqueous 5% KH/MeOH to 25-hydroxycholesterol.
.
' 10770Z~
The 25-hydroxycholesterol was dissolved in dioxane and boiled with 2, 3-dichloro-5, 6-dicyanobenzo-quinone (DDQ) to obtain 25-hydroxy-cholesta-1,4-diene-3-one. This latter compound was subjected to dehydrogenation with chloroanil in the presence of the reduced derivative of DDQ-hydroquinone (2HD~Q) to obtain 25-hydroxy-cholesta- 1, 4, 6-triene-3-one. Alternatively, 25-hydroxy-cholesta- 1, 4, 6-trien-3-one can be obtained by DDQ oxidation of 25-hydroxycholesterol a. J.
Partridge et al, Helv. Chim. Acta 57, 764 (1974))which was converted from 6,~-methoxy-25-hydroxy-3~, 5-cyclo-5~-cholestane.
The cholesta l, 4, 6-trien-3-on-25-ol (IX) is subjected to isomeri-zation in the presence of a basic catalyst whereby the two double bonds located at ~ 4' 5 and a6' 7 positions are isomerized to ,5 ' and ~ 7~ 8 positions respectively. Although any of the well known basic catalysts which promote such isomerization can be used the preferred catalysts _ .
are the alcoholates, such as methylates, ethylates and particularly potassium t-butoxide.
The isomerization is preferably carried out in a solvent which has a high dissol~,ing power for the starting compound including, in general, organic solvents such as ethers, benzene type solvents and hydrocarbon solvents. Solvents such as ether (ethyl), isopropyl ether, tetrahydrofuran, dimethylsulfoxide, and tertiary butyl alcohol find ready application. Excellent results are obtained when, for example, dimethyl-sulfoxide as the solvent and potassium t-butoxide as the catalyst are used in combination for the isomerization reaction. In addition, it is desirable that the reaction be carried out in an atmosphere of inert gas such as argon or nitrogen.
The isomerization reaction can be carried out over a reasonably -broad temperature range although the preferred range is from about 0 tO about 200 C. Higher or lower temperatures may be used but find practical limits in their inlluence upon time of reaction, stability, or instability of reactants to certain temperatures, The compound (VllI) is isolated from the reaction mixture according to a customary procedure, for example, by neutralizing the resulting reaction mixture liquid, extracting it, concentrating the extract and subjecting the concentrate to column chromatography or the like. Because of yield considerations, however, it is preferred that the reaction mixture be forwarded to the next step directly without isolation of the compound (VIII).
The compound (VII) is obtained by reducing compound (VIII) with a metal hydride. Metal hydrides suitable for such reduction, are, for example, lithium aluminum hydride, metal boron hydrides such as sodium boron hydride, potassium boron hydride or lithium boron hydrides, so~ium borohydride and calcium borohydride. It is preferred that the reduction reaction be carried out in a solvent, and use of an ether type solvent such as ether, tetrahydrofuran, 1,2-dimethoxyethane, diglyme (diethylene glycol dimethyl ether3 and the like~ When sodium borohydride or calcium borohydride is used as the metal hydride, a hydroxyl group-containing solvent such as water, methanol and ethanol can be used. The reaction temperature is suitably chosen within a range of from lowered temperatures to elevated temperatures. The preferred temperatur,e range for the reaction is from about 0 C. to about 200 C.
Isolation of the compound (VIl) from the reaction mixture can be accomplished according to customary methods, for example, by neutralizing and extracting the reaction mixture liquid, concentrating the extract and subjecting the concentrate to column chromatography or the like. lt is possible to forward the reaction mixture directly to the subsequent step without isolation of the compound (VlI).
The compound (V) is prepared by reacting compound (VII) with comp~und (Vl). It is preferred that the reaction be carried out in a solvent that does not participate in the reaction.
In general, use of organic solvents such as ethers, benzene-type solvents and hydrocarbon solvents is preferred. Specific examples of preferred solvents are benzene, tetrahydrofuran and methylene chloride.
The reaction temperature is suitably chosen within a range of from lower temperatures to elevated reflux temperatures.
ln the 1, 2, 4-triazoline-3, 5-dione derivative represented by the general formula (VI), any of organic residues inactive to the reaction can be used as R. With the preferred solvents for the reaction it is generally preferred that R be a monocyclic aromatic residue or a lower alkyl group. Specific examples of such preferred organic residues are phenyl, mono-sub3tituted phenyl, methyl and ethyl grQupS.
Isolation of the compound (V) from the reaction mixture is performed by concentrating the reaction mixture, extracting the con-centrate with a solvent such as benzene or methylene chloride, and subjecting the extract to column chromatography.
The compound (IV) is prepared by react ing compound (V) with a peroxide. An organic peracid is preferably used as the peroxide.
As the peracid, there can be employed, aromatic peracids such as perbenzoic acid and m-chloroperbenzoic acid and aliphatic peracids such as permaleic acid, peracetic acid and pertrifluoroacetic acid.
lt is preferred that the reaction be carried out in a solvent, for example, ~0770Z8 ethers, such as ethyl ether and tetrahydrofuran chlorinated hydrocarbon solvents, such as chloroform and methylene chloride, alkyl esters of organic acids such as ethyl acetate, and fatty acids such as acetic acid the peroxide being present in an amount of about 1 to 5 moles per mole of compound V. In view of the inactivity toward the peroxide used and the dissolving power toward the reactants, use of hydrocarbon solvents such as methylene chloride and chloroform is especially preferred. The reaction temperature is chosen within a rarlge of from lowered temperatures to elevated temperatures depending on the kind of the peroxide used.
The compound (lIl) is obtained by reducing compound (IV) ~
with a metal hydride. The metal hydrides which are preferably employed are lithium aluminum hydride and lithium borohydride. The reaction is normally carried out in a solvent, such as the ether type solvents, for example, ethyl ether, tetrahydrofuran, 1,2-dimethoxyethane and diglyme, which are especially preferred. The reaction temperature .
is chosen suitably within a range of from lowered tempexatures to elevated temperatures, for example from about 50 to about 150~ C.
Isolation of the compound (lIT) from the reaction mixture is performed according to customary methods, e. g. by decomposing the excessive metal hydride, extractlng the reactl;on mixture, concentrating the extract and subjecting the concentrate to column chromatography or the like.
Compound (III) is then irradiated with ultraviolet rays to form compound (II) in which the ring B of the steroid skeleton is cleaved.
The irradiation IS generally conducted in a solvent. Hydrocarbon-type solvents, ether-type solvents and alcohols can be readily employed.
1~770Z~3 Examples of preferable hydro_arbon-type solvents are saturated hydrocarbon solvents, especially those having a low boiling point, such as hexane and octane. Ether type solvents which are preferably employed are the low-boiling-point saturated ethers, such as ethyl ether and tetrahydrofuran and the preferable alcohols are the lower alcohols such as methanol and ethanol. It is preferred that the reaction be carried out at a temperature approximating room temperature and in an atmosphere of an inert gas such as argon. The time for irradiation of ultraviolet rays varies depending upon the intensity of the ultraviolet source lamp and the reaction scale. In general, the irradiation time is within a range of from scores of seconds to several hours.
Compound (II) is isolated from the reaction mixture according to customary methods, for example; by concentrating the reaction mixture and subjecting the concentrate to chromatography or the like. It is possible .. ~
to forward the reaction mixture to the subsequent step directly without isolation of the compound (II).
The compound (I) is formed by isomerizing the compound (II) with thermal equilibrium being established between the compound (II) and the desired end compound (I). The isomerization reaction is carried out in accordance with known and customary methods, for example, by allowing the compound (II) to stand for a period in the dark at room temperature, or by heating it in a solvent. Any solvents which are inactive to the reaction e. g., hydrocarbon-type s~lvents, ether-type solvents and alcohols can be used. Preferred solvents are those having a low boiling point and a high dissolving power for the compound (II), such as hexane, isoctane, toluene, ether and te~rahydrofuran. Depending upon the reaction conditions the reaction tlme may range from several hours ~ 0770Z8 tO several weeks. \7\1hen cornpound (II) is allowed to stand in the dar};, it is preferred that the reaction continue for several weeks, When ~he reaction is carried out under heating and refluxing, it is preferred thal the reaction continue only for several hours.
Isolation of the end product, 1~, 25-dihydroxycholecalciferol from the reaction mixture is accomplished by known and custornary purification means such as extraction, recrystallization, column chromatography and partition chromatography. Column chromatography using a column packed with Sephadex (manufactured by Pharmacia Pine Chemicals) is especially effective. I~nisomerized compound (II) is also obtained in the separation procedure and this unisomerized compound (II) can be recycled for further isomerization after recovery.
- Each of intermediate compounds (VlII), (VII), (V), (IV), (III) and (II) formed in the process of this invention are novel and form another . ~ ., aspect of this i~vention.
A more complete understandlng of the invention can be obtained from reference to the following sp~cific examples which are included for purposes of illustration only and are not intended to belimiting.
Example 1 1. Preparation of cholesta- 1, 5, 7-trien-3-on-25-ol.
A reaction vessel was charged with 125 ml of dry dimethylsulfoxide and 2. 5 g of choles$a-1, 4, 6-trien-- 3-on-25-ol was suspended in the dimethylsulfoxide. The suspension was heated, and 10 ml of dry ether was added to the resulting milky suspension tO obtain a transparent solution. ~he reaction vessel was filled wilh dry argon gas. Powdery potassium t-buloxide prepared from 1. 25 g potassium` and 50 ml of butanol was added al one time to the solution under ice cooling and wilh violenl agilalion.
*Trade Mark - 1 l -~0770Z8 The reaction mixture liquid was violently agitated for 12 minutes and was then poured into ice water saturated with carbon dioxide gas, which was prepared by adding dry ice to water. The mixture was then extracted with 600 ml of ether cooled to 0 to S C. The extract was promptly washed with cooled water saturated with a large quantity of carbon dioxide until the washing liquid became neutral, and the ether was then distilled off to obtain crude cholesta- 1, 5, 7-trien-3-on-25-ol.
2. Preparation of cholesta-l, 5, 7-triene-3~, 25-diol.
100 ml of an ethanol solution containing 2. 5 g of sodium borohydride was added dropwise under agitation - -to 110 ml of methanol containing 4. 9 g of calcium chloride, which was cooled below - 10 C. The mixture was agitated for 20 minutes while maintaining the temperature at about -10 C. Then, 100 ml of the ether solution containing crude cholesta- 1, 5, 7-trien-3-on-25-ol, which was prepared in 1.
above, was added dropwise to the above mixture. The reaction mixture was further agitated at -10 C. for 1 hour and at 0 C. for 1 hour, and was then neutralized with 10% acetic acid after which the solvent was distilled off under reduced pressure. The residue was extracted with methylene chloride and the extract was washed with water and dried with magnesium sulfate. Methylene chloride was distilled off to obtain crude cholesta- 1, 5, 7-triene-3~, 25-diol (about 1 g).
3. Preparation of 1,4-cyclized adduct of cholesta-1,5,7-triene-3~B, 25-diol and 4-phenyl- 1, 2, 4-triæoline-3, S-dione.
About S00 mg of 4-phenyl-1,2,4-triæoline-3,5-dione was added little by little under agitation to 50 ml of a methylene chloride solution containing the crude cholesta-1,5,7-triene-3~,25-diol ~about 1 g)obtained in 2. above, until the methylene chloride solution became red. 'rhe solution was agitated at room temperature for 1 hour, and methylene chloride was distilled off and the residue was subjected to column chromatography using a column packed with 200 g of alumina. A chloroform effluent fraction was collected and recrystallized from methand to obtain 1. 4 g (the overall yield being 38.1%) ~, . .
of a cyclic adduct of cholesta-1,5,7-triene-3,~,25-diol and 4-phenyl-1,2,4-triazoline-3,5-dione having a meltin~
point of 159 to 160 C.
Elementary Analysis Values as C35H4704N3- 1/2H2O:
Calculated: C = 72. 13%, H = 8. 30~57c~ N = 7. 21%
Found: C - 72. 06%, H = 8. 15%, N = 7. 45%
Example 2 197. 3 mg of the 1, 4-cyclic adduct obtained in Exarnple 1 was dissolved in 5 ml of chloroform and 237 mg of m-chloroperbenzoic acid was added to the solution after which the mixture was agitated for 40 hours at room temperature. The reaction mixture liquid was diluted with chloroform, washed with a lO~YC aqueous solution of potassium carbonate, dried with anydrous magnesium 107702~i sulfate, and the solvenL was distilled off under reduced pressure. The residue was subjected to silica gel column chromatography. A 1~, 2,~-epoxide of the 1, 4-cyclic adduct melting at 159 to 160. 5 C. was recovered from a fraction primarily eluted with methanol-containing ether, and from the subsequent fraction was obtained 68. 3 mg of a 1~,2~r-epoxide of the 1,4-cyclic adduct having a melting point of 162 to 163. S C. (as measured with respect to a product recrystallized from methanol).
Elementary Analysis Values as C35H47OSN3- 1/2H2O:
Calculated: C = 70.21~C, H - 8. 03~c, N - 7.02%
Found: C = 70. 02%, H - 7. 83%, N = 7. 03%
Example 3 Preparation of cholesta-5, 7-diene- 1~, 3~, 25-triol.
. ~
140. 3 g of the 1~, 2~-epoxide of the 1, 4-cyclic adduct of cholesta- 1, 5, 7-triene-3,8, 25-diol and 4-phenyl- 1-2, 4-triazoline-3,5-dione obtained in Example 2 was dissolved in 15 ml of tetrahydrofuran, and 142 mg of lithium aluminum hydride was added little by little to the solution under agitation. Then, the mixture was mildly refluxed and boiled for 1 hour and cooled, and 20 ml of tetrahydrofuran was added to the reaction mixture. A saturated aqueous solution of Glauber salt was added to the reaction mixture until generation of bubbles was stopped, whereby excessive lithium aluminum hydride was decomposed. The reaction mixture was then filtered, and the residue was washed 3 times with 10 ml of tetrahydrofuran. The organic solvent - 1~ -107'70Z8 layer was dried and the solvent was distilled off, The residue was purified by using a column packed with 20 g of Sephadex LH_20, and a fraction eluted by chloroform-hexane (65: 35 V/V ratio) was collected and recrystallized from ether-hexane to obtain 49. 9 mg of cholesta-5, 7-diene- lc, 3~, 25-t~iol in the form of needles melting at 149 to 152 C.
Mass Spectrum: mk 416(M+), 398, 380, 362 UV Spectrum: il. 2 263, 272, 282, 294 m,u max ~xaniple 4 Preparation of 1~,25-dihydroxyprevitamin D3.
A soluti~n of 31. 5 mg of cholesta-5, 7-d~ene-1~, 3~, 25-triol in 380 ml of ether was exposed for 1 minute to ultraviolet rays through;a Vycor filter in an argon gas atmosphere by using a 400-W high pressure mercury lamp (manufactured by Toshiba). The solvent was distilled off at room ternperature under reduced pressure, and the residue was subjected to colurnn chromatography sing a column packed with 20 g of ~ephadex LH-2~. From a fraction primarily eluted by chloroform-hexane (65: 35 . . . .
V/V Tatio) was obtained 10. 5 mg of oily- 1~, 25-dihydroxy-previtamin D3 ~having a maximum ultraviolet absorption at 260 m,u in an ether solution), and from the subsequent fraction was recovered 14. 3 mg of cholesta-5, 7-diene~
3~, 25-triol. When Ihis compound was exposed IO ultraviolet rays in the same manner as above, 4. 5 mg of lc~, 25-dihydroxy-;
previtamin D3 was obtained.
*Trade Mark 1~ - .
Example 5 Preparation of l ~, 25- dih~droxycholecalci~erol.
The 1~,25-dihydroxyprevitamin D3 obtained in Example 4 above was dissolved in 100 ml of ether, and the solution was allowed to stand at room temperature in the dark in a vessel filled with argon gas for 2 weeks, during which the position of the maxirnum ultraviolet absorp;ion was shifted from 260 m}l to 264 m,~ and the absorption intensity was increased to l. 6 times the initial intensity. The solvent was distilled off under reduced pressure and the residue was subjected to chromatography using a column packed with 10 g of $ephadex LH-20. From a fraction eluted by chloroform-hexane (65: 35 v!v ratio) was obtained 9. 3 mg of oily 1~, 25-dihydrox$~cholecalciferol ~ ..... .
having a melting point of 9i to 99~ C. (as measured with respect to a needle crystal recrystallized from chloroform).
Mass Spectrum: m/e416(M~), 398, 380, 362, 269, 251, 152, 134 UV Spectrum: ~ 264 m,u x lt will be apparent to one of ordinary skill in the art that in the foregoing Examples other solvents and reactants, as well as reaction conditions cornp~tible with such solvents and reactants, such as those set forth in the foregoing specification, can be employed with comparable results.
. . .' .: :
* Trade Mark -- 1( -- .
Claims (12)
1. A process for preparing cholesta-5,7-diene-1.alpha.,3.beta.,25-triol which comprises reducing a 1.alpha.,2.alpha.-epoxide of the formula wherein R represents an organic residue, with a metal hydride and thereafter isolating cholesta-5,7-diene-1.alpha.,3.beta.,25-triol.
2. The process as claimed in claim 1 wherein the metal hydride is lithium aluminum hydride or lithium boro-hydride.
3. The process as claimed in claim 1 wherein the reduction is carried out in the presence of a solvent.
4. The process as claimed in claim 3 wherein the solvent is an ether type solvent.
5. The process as claimed in claim 3 wherein the solvent is ethyl ether, tetrahydrofuran, 1,2-dimethoxyethane or diglyme.
6. The process as claimed in claim 1 wherein the reduction is carried out within the temperature range of from about 50°C to about 150°C.
7. The process as claimed in claim 1 wherein the 1.alpha.,2.alpha.-epoxide has the stated formula wherein R represents a phenyl radical.
8. The process as claimed in claim 1 wherein the 1.alpha.,2.alpha.-epoxide is the 1,4-cyclic adduct of cholesta-1,5,7-triene-3.beta.,25-diol and 4-phenyl-1,2,4-triazoline-3,5-dione and the reaction is carried out in the presence of tetra-hydrofuran as solvent using lithium aluminum, hydride as the metal hydride.
9. Cholesta-5,7-diene-1.alpha.,3.beta.,25-triol whenever prepared by the process of claim 1, 2 or 3.
10. Cholesta-5,7-diene-1.alpha.,3.beta.,25-triol whenever prepared by the process of claim 4, 5 or 6.
11. Cholesta-5,7-diene-1.alpha.,3.beta.,25-triol whenever prepared by the process of claim 7.
12. Cholesta-5,7-diene-1.alpha.,3.beta.,25-triol whenever prepared by the process of claim 8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA329,124A CA1077028A (en) | 1975-02-28 | 1979-06-05 | PROCESS FOR PREPARATION OF 1.alpha.,2.alpha.-DIHYDROXY-CHOLECALCIFEROL |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP50023827A JPS51100056A (en) | 1975-02-28 | 1975-02-28 | 1 arufua 255 jihidorokishikorekarushifuerooruno seiho |
| CA245,926A CA1069939A (en) | 1975-02-28 | 1976-02-17 | PROCESS FOR PREPARATION OF 1.alpha.,25-DIHYDROXYCHOLECALCIFEROL |
| CA329,124A CA1077028A (en) | 1975-02-28 | 1979-06-05 | PROCESS FOR PREPARATION OF 1.alpha.,2.alpha.-DIHYDROXY-CHOLECALCIFEROL |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1077028A true CA1077028A (en) | 1980-05-06 |
Family
ID=27164335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA329,124A Expired CA1077028A (en) | 1975-02-28 | 1979-06-05 | PROCESS FOR PREPARATION OF 1.alpha.,2.alpha.-DIHYDROXY-CHOLECALCIFEROL |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1077028A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4341774A (en) * | 1979-08-10 | 1982-07-27 | Chugai Seiyaku Kabushiki Kaisha | Method for suppressing abnormal rise in immunological function and agent useful therefor |
-
1979
- 1979-06-05 CA CA329,124A patent/CA1077028A/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4341774A (en) * | 1979-08-10 | 1982-07-27 | Chugai Seiyaku Kabushiki Kaisha | Method for suppressing abnormal rise in immunological function and agent useful therefor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112608361B (en) | Process for preparing cholesterol, derivatives and analogues thereof | |
| US3901928A (en) | 1' ,3' -dihydroxy steroid-5-enes method of preparing same and their use for preparing 1' -hydroxy-25-hydrogen vitamin d compounds | |
| FUKUOKA et al. | Chemical and toxicological studies on bracken fern, Pteridium aquilinum var. latiusculum. II. Structures of pterosins, sesquiterpenes having 1-indanone skeleton | |
| Wiersig et al. | Stereospecific synthesis of the side chain of the steroidal plant sex hormone oogoniol | |
| US4022768A (en) | Process for preparation of 1α,25-dihydroxycholecalciferol | |
| IE50195B1 (en) | Process for preparing 1alpha-hydroxyvitamin d compounds from 1alpha-hydroxy-3,5-cyclovitamin d compounds | |
| Li et al. | Sterol synthesis. Preparation and characterization of fluorinated and deuterated analogs of oxygenated derivatives of cholesterol | |
| Wilson et al. | Concerning the chemical synthesis of 3β-hydroxy-5α-cholest-8 (14)-en-15-one, a novel regulator of cholesterol metabolism | |
| CA3136914A1 (en) | Novel method for synthesizing 25-oh cholesterol/calcifediol from phytosterol | |
| CA1069939A (en) | PROCESS FOR PREPARATION OF 1.alpha.,25-DIHYDROXYCHOLECALCIFEROL | |
| Morris et al. | Structure and synthesis of 25-hydroxycholecalciferol-26, 23-lactone, a metabolite of vitamin D | |
| CA1077028A (en) | PROCESS FOR PREPARATION OF 1.alpha.,2.alpha.-DIHYDROXY-CHOLECALCIFEROL | |
| GB2058793A (en) | Process for preparing 1-hydroxylated vitamin d compounds from 5,6-transvitamin d compounds | |
| Pettit et al. | Steroids and Related Natural Products. VII. Boron Trifluoride Etherate—Lithium Aluminum Hydride Reduction of Smilagenin Acetate1, 2 | |
| Taylor et al. | Synthesis of cholest-5-ene-3. beta., 11. alpha. 15. beta.-triol-7-one. A model for the steroid nucleus of oogoniol, a sex hormone of the water mold Achlya | |
| US3929770A (en) | Process for preparation of steroid derivative | |
| JPS61106567A (en) | 24,25-dihydroxycholecalciferol | |
| US4038272A (en) | Stereospecific syntheses of 24r,25- and 24s,25-dihydroxycholesterol and alkanoyl derivatives thereof | |
| EP0070588A1 (en) | Method of preparing 1-alpha-hydroxyvitamin D and 1-alpha-hydroxy-previtamin D compounds, and adduct of a previtamin D or tachysterol compound with a suitable dienophile | |
| Beckwith et al. | Reactions of organic compounds in adsorbed monolayers. I. Ozonation of 3, 7-dimethyloctyl acetate | |
| Hernando et al. | Influence of the substitution pattern on the Pb (OAc) 4 mediated oxidative cleavage of steroidal 1, 2-diols | |
| Takashi et al. | Potential bile acid metabolites. 16. Synthesis of stereoisomeric 3α, 6, 7, 12α-tetrahydroxy-5β-cholanoic acids | |
| CA2062520C (en) | Synthesis of 1-alpha-hydroxy-secosterol compounds | |
| US2260085A (en) | Process for the preparation of synthetic antirachitic provitamins and vitamins | |
| Baillie et al. | Synthesis of specifically deuterium-labelled pregnanolone and pregnanediol sulphates for metabolic studies in humans |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |